{
    "info": {
        "nct_id": "NCT02966782",
        "official_title": "A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes",
        "inclusion_criteria": "* Subjects who have relapsed or refractory MDS.\n* Subject enrolled in venetoclax monotherapy must have documented failure of prior therapy with a hypomethylating agent (HMA). HMA-failure is defined as:\n\n  1. Relapse after initial complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years, OR\n  2. Failure to achieve complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years\n* Subjects must have presence of < 20% bone marrow blasts per bone marrow biopsy/aspirate at screening.\n* Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT).\n* Subject must have an Eastern Cooperative Oncology Group (ECOG) performance score of ≤2.\n* Subject must have adequate hematologic, renal, and hepatic function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Subject has received prior therapy with a BH3 mimetic.\n* Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).\n* Subject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.\n* Subject has received allogeneic HSCT or solid organ transplantation.\n* Subject has received a live attenuated vaccine within 4 weeks prior to the first dose of study drug.\n* Subject is pregnant or breastfeeding.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Subjects must have presence of < 20% bone marrow blasts per bone marrow biopsy/aspirate at screening.",
            "criterions": [
                {
                    "exact_snippets": "presence of < 20% bone marrow blasts per bone marrow biopsy/aspirate at screening",
                    "criterion": "bone marrow blasts",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 20,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject must have an Eastern Cooperative Oncology Group (ECOG) performance score of ≤2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance score of ≤2",
                    "criterion": "ECOG performance score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject must have adequate hematologic, renal, and hepatic function.",
            "criterions": [
                {
                    "exact_snippets": "adequate hematologic ... function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT).",
            "criterions": [
                {
                    "exact_snippets": "Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT)",
                    "criterion": "candidate for allogenic hematopoietic stem cell transplantation (HSCT)",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject enrolled in venetoclax monotherapy must have documented failure of prior therapy with a hypomethylating agent (HMA). HMA-failure is defined as:",
            "criterions": [
                {
                    "exact_snippets": "Subject enrolled in venetoclax monotherapy",
                    "criterion": "venetoclax monotherapy enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have documented failure of prior therapy with a hypomethylating agent (HMA)",
                    "criterion": "prior therapy with hypomethylating agent (HMA)",
                    "requirements": [
                        {
                            "requirement_type": "failure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects who have relapsed or refractory MDS.",
            "criterions": [
                {
                    "exact_snippets": "Subjects who have relapsed or refractory MDS",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).",
            "criterions": [
                {
                    "exact_snippets": "Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)",
                    "criterion": "myelodysplastic syndrome (MDS) evolving from pre-existing myeloproliferative neoplasm (MPN)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received a live attenuated vaccine within 4 weeks prior to the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "received a live attenuated vaccine within 4 weeks prior to the first dose of study drug",
                    "criterion": "live attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received allogeneic HSCT or solid organ transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Subject has received allogeneic HSCT",
                    "criterion": "allogeneic HSCT",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject has received ... solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject is pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Subject is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received prior therapy with a BH3 mimetic.",
            "criterions": [
                {
                    "exact_snippets": "Subject has received prior therapy with a BH3 mimetic",
                    "criterion": "prior therapy with a BH3 mimetic",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.",
            "criterions": [
                {
                    "exact_snippets": "Subject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.",
                    "criterion": "MDS/MPN diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "subtypes",
                            "expected_value": [
                                "chronic myelomonocytic leukemia (CMML)",
                                "atypical chronic myeloid leukemia (CML)",
                                "juvenile myelomonocytic leukemia (JMML)",
                                "unclassifiable MDS/MPN"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "2. Failure to achieve complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years",
            "criterions": [
                {
                    "exact_snippets": "Failure to achieve complete or partial response or hematological improvement",
                    "criterion": "treatment response",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": [
                                "complete response",
                                "partial response",
                                "hematological improvement"
                            ]
                        },
                        {
                            "requirement_type": "achievement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 4 cycles of azacitidine",
                    "criterion": "azacitidine treatment",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 4 cycles of decitabine",
                    "criterion": "decitabine treatment",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within the last 5 years",
                    "criterion": "treatment timing",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Relapse after initial complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years, OR",
            "criterions": [
                {
                    "exact_snippets": "Relapse after initial complete or partial response or hematological improvement",
                    "criterion": "relapse",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "after initial complete or partial response or hematological improvement"
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 4 cycles of azacitidine",
                    "criterion": "azacitidine treatment",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 4 cycles of decitabine",
                    "criterion": "decitabine treatment",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within the last 5 years",
                    "criterion": "treatment timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}